BWAY vs. KRMD, ALUR, BLUA, TELA, STIM, NVNO, SEPA, MGRM, SRTS, and PDEX
Should you be buying BrainsWay stock or one of its competitors? The main competitors of BrainsWay include KORU Medical Systems (KRMD), Allurion Technologies (ALUR), BlueRiver Acquisition (BLUA), TELA Bio (TELA), Neuronetics (STIM), enVVeno Medical (NVNO), SEP Acquisition (SEPA), Monogram Orthopaedics (MGRM), Sensus Healthcare (SRTS), and Pro-Dex (PDEX). These companies are all part of the "surgical & medical instruments" industry.
BrainsWay (NASDAQ:BWAY) and KORU Medical Systems (NASDAQ:KRMD) are both small-cap medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their community ranking, earnings, profitability, institutional ownership, valuation, media sentiment, dividends, analyst recommendations and risk.
BrainsWay received 26 more outperform votes than KORU Medical Systems when rated by MarketBeat users. Likewise, 64.58% of users gave BrainsWay an outperform vote while only 60.00% of users gave KORU Medical Systems an outperform vote.
30.1% of BrainsWay shares are held by institutional investors. Comparatively, 58.6% of KORU Medical Systems shares are held by institutional investors. 19.0% of BrainsWay shares are held by company insiders. Comparatively, 25.6% of KORU Medical Systems shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
BrainsWay has higher revenue and earnings than KORU Medical Systems. BrainsWay is trading at a lower price-to-earnings ratio than KORU Medical Systems, indicating that it is currently the more affordable of the two stocks.
BrainsWay has a net margin of -4.83% compared to KORU Medical Systems' net margin of -45.24%. BrainsWay's return on equity of -3.98% beat KORU Medical Systems' return on equity.
BrainsWay has a beta of 1.18, suggesting that its stock price is 18% more volatile than the S&P 500. Comparatively, KORU Medical Systems has a beta of 0.55, suggesting that its stock price is 45% less volatile than the S&P 500.
BrainsWay currently has a consensus target price of $9.67, suggesting a potential upside of 78.35%. KORU Medical Systems has a consensus target price of $3.50, suggesting a potential upside of 56.25%. Given BrainsWay's higher probable upside, equities research analysts plainly believe BrainsWay is more favorable than KORU Medical Systems.
In the previous week, BrainsWay had 16 more articles in the media than KORU Medical Systems. MarketBeat recorded 19 mentions for BrainsWay and 3 mentions for KORU Medical Systems. BrainsWay's average media sentiment score of 0.81 beat KORU Medical Systems' score of 0.46 indicating that BrainsWay is being referred to more favorably in the media.
Summary
BrainsWay beats KORU Medical Systems on 12 of the 18 factors compared between the two stocks.
Get BrainsWay News Delivered to You Automatically
Sign up to receive the latest news and ratings for BWAY and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding BWAY and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
BrainsWay Competitors List
Related Companies and Tools
